These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30535452)

  • 1. Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia.
    Jiang M; Zou X; Lu L
    Oncol Rep; 2019 Feb; 41(2):885-894. PubMed ID: 30535452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
    Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
    Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.
    Francis OL; Milford TA; Martinez SR; Baez I; Coats JS; Mayagoitia K; Concepcion KR; Ginelli E; Beldiman C; Benitez A; Weldon AJ; Arogyaswamy K; Shiraz P; Fisher R; Morris CL; Zhang XB; Filippov V; Van Handel B; Ge Z; Song C; Dovat S; Su RJ; Payne KJ
    Haematologica; 2016 Apr; 101(4):417-26. PubMed ID: 26611474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
    Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
    Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between CD9 and PI3K‑p85 activates the PI3K/AKT signaling pathway in B‑lineage acute lymphoblastic leukemia.
    Shi YF; Huang ZY; Huang YS; Dong RJ; Xing CY; Yu K; Leung KT; Feng JH
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.
    Chiaretti S; Brugnoletti F; Messina M; Paoloni F; Fedullo AL; Piciocchi A; Elia L; Vitale A; Mauro E; Ferrara F; De Fabritiis P; Luppi M; Ronco F; De Propris MS; Raponi S; Kronnie GT; Vignetti M; Guarini A; Foà R
    Leuk Res; 2016 Feb; 41():36-42. PubMed ID: 26754556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
    Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
    PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
    Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
    Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Salidroside via ERK1/2 and PI3K/AKT/mTOR signal pathway induces mouse bone marrow mesenchymal stem cells differentiation into neural cells].
    Chen YN; Liu H; Zhao HB; Liu Y; Bai J; Zhu XJ; Wang Y
    Yao Xue Xue Bao; 2013 Aug; 48(8):1247-52. PubMed ID: 24187831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia.
    Alkashgari HR; Ruiz-Jimenez C; Stoian C; Coats JS; Baez I; Chirshev E; Martinez SR; Dovat S; Francis-Boyle OL; Casiano CA; Payne KJ
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qiliqiangxin protects against anoxic injury in cardiac microvascular endothelial cells via NRG-1/ErbB-PI3K/Akt/mTOR pathway.
    Wang J; Zhou J; Wang Y; Yang C; Fu M; Zhang J; Han X; Li Z; Hu K; Ge J
    J Cell Mol Med; 2017 Sep; 21(9):1905-1914. PubMed ID: 28271613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of USP1 induces apoptosis via ID1/AKT pathway in B-cell acute lymphoblastic leukemia cells.
    Kuang X; Xiong J; Lu T; Wang W; Zhang Z; Wang J
    Int J Med Sci; 2021; 18(1):245-255. PubMed ID: 33390793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
    Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
    Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression.
    Yano M; Imamura T; Asai D; Moriya-Saito A; Suenobu S; Hasegawa D; Deguchi T; Hashii Y; Kawasaki H; Hori H; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Matsumoto K; Kiyokawa N; Oda M; Sato A;
    Genes Chromosomes Cancer; 2014 Oct; 53(10):815-23. PubMed ID: 24935070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the PI3K/Akt/mTor pathway using
    Phyu SM; Tseng CC; Fleming IN; Smith TA
    Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.
    Ge Z; Gu Y; Zhao G; Li J; Chen B; Han Q; Guo X; Liu J; Li H; Yu MD; Olson J; Steffens S; Payne KJ; Song C; Dovat S
    Oncotarget; 2016 Aug; 7(31):49722-49732. PubMed ID: 27391346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.